Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Morgan Stanley analyst Thibault Boutherin initiated coverage of Novartis (NVS) with an Underweight rating and CHF 91 price target The company has a solid outlook but limited earnings upside aside ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.